Research programme: kainate receptor antagonists - Biotie Therapies

Drug Profile

Research programme: kainate receptor antagonists - Biotie Therapies

Alternative Names: E099-255011; GluR5 receptor antagonists; GluR6 receptor antagonists

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator elbion GmbH
  • Developer biocrea GmbH
  • Class Indoles; Small molecules
  • Mechanism of Action Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Germany
  • 14 Nov 2008 elbion GmbH has been acquired by BioTie Therapies
  • 04 Sep 2008 Early research in Neurodegenerative disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top